• Twitter
  • Facebook
  • LinkedIn
Biweekly newsletter of the International Cytokine & Interferon Society

Biweekly newsletter of the International Cytokine & Interferon Society

Signals+ Editors: Daniella Schwartz & Di Yu (Editors in Chief), Saurabh Chattopadhyay, Zhian Chen, Mohamed Saad & Maialen Sebastian-delaCruz
  • Subscribe
  • Archives
    • Archives (Oct. 2023 and before)
      • Signals+ October 2022 PDF
      • Signals+ April 2021 PDF
      • Signals+ April 2022 PDF
  • Awards
  • Annual Meeting
  • Member News
    • Member Highlights
    • Members in the News
    • Members on the Move
    • New Member Mini-Bios
    • Articles of Interest
    • Reviews of Interest
  • Society News
    • President’s Letter
    • Featured Article!
  • Industry News
    • Industry Partner News
    • Other Meetings
    • Clinical Trials
HomeClinical TrialsPegylated Interferon Alfa-2b

Pegylated Interferon Alfa-2b

March 2, 2025 Clinical Trials

Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Adult Essential Thrombocythemia

ClinicalTrials.gov ID NCT05395507
Sponsor Institute of Hematology & Blood Diseases Hospital, China

Share this:

  • Click to share on Bluesky (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on WhatsApp (Opens in new window)
  • Click to email a link to a friend (Opens in new window)
Previous

Recombinant Interleukin-15

Prof Kim Good-JacobsonNext

Member Highlight: Meet Kim Good-Jacobson, PhD

Immunology Group in a lab
Special Article of Interest

Challenges and Opportunities of Conducting High-Quality Research in Cytokine Biology and Immunology in Low- and Middle-Income Countries

March 3, 2025

The following perspective is by ICIS Member, Javier Mora, Ph.D., University of Costa Rica, Faculty of Microbiology. We welcome your comments and feedback, either to Prof. Mora (javierfrancisco.mora @ ucr.ac.cr) directly or to the ICIS Managing Director, Stephanie Flores (sflores @ cytokinesociety.org). Research in cytokines and immunology plays a pivotal [READ MORE]

Share this:

  • Click to share on Bluesky (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on WhatsApp (Opens in new window)
  • Click to email a link to a friend (Opens in new window)
Prof Kim Good-Jacobson
Member Highlights

Member Highlight: Meet Kim Good-Jacobson, PhD

March 3, 2025

The following interview was conducted by Signals+ Editor Maialen Sebastian-delaCruz, Ph.D. Connect with her on LinkedIn. My lab in Australia works on understanding how humoral memory is formed, and how this goes awry in chronic infection. I’m excited to be able to learn and make new collaborations from joining the Cytokine Society, so [READ MORE]

Share this:

  • Click to share on Bluesky (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on WhatsApp (Opens in new window)
  • Click to email a link to a friend (Opens in new window)
No Picture
Clinical Trials

Pegylated Interferon Alfa-2b

March 2, 2025

Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Adult Essential Thrombocythemia ClinicalTrials.gov ID NCT05395507 Sponsor Institute of Hematology & Blood Diseases Hospital, China

Share this:

  • Click to share on Bluesky (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on WhatsApp (Opens in new window)
  • Click to email a link to a friend (Opens in new window)
No Picture
Clinical Trials

Recombinant Interleukin-15

March 2, 2025

Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers ClinicalTrials.gov ID NCT03388632 Sponsor National Cancer Institute (NCI) Information provided by National Institutes of Health Clinical Center (CC) (National Cancer Institute (NCI)) (Responsible Party)

Share this:

  • Click to share on Bluesky (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on WhatsApp (Opens in new window)
  • Click to email a link to a friend (Opens in new window)
No Picture
Clinical Trials

Role of IL-5R Signaling

March 2, 2025

Role of IL-5R Signaling in Non-eosinophil Upper Airway Cells in CRSwNP (RECAP-5) ClinicalTrials.gov ID NCT05672030 Sponsor Brigham and Women’s Hospital Information provided by Tanya Laidlaw, MD, Brigham and Women’s Hospital (Responsible Party)

Share this:

  • Click to share on Bluesky (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on WhatsApp (Opens in new window)
  • Click to email a link to a friend (Opens in new window)

International Cytokine & Interferon Society, Copyright 2024 Website Design by Rhema Association Management | Privacy Policy

Go to mobile version